Published in Proc Natl Acad Sci U S A on May 04, 2007
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Lipids and membrane microdomains in HIV-1 replication. Virus Res (2009) 1.51
Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48
Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection. J Virol (2008) 1.28
The Role of Lipids in Retrovirus Replication. Viruses (2010) 1.07
Virion stiffness regulates immature HIV-1 entry. Retrovirology (2013) 0.95
C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. J Gen Virol (2012) 0.93
Recent progress in antiretrovirals--lessons from resistance. Drug Discov Today (2008) 0.92
Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence. J Virol (2008) 0.90
The frantic play of the concealed HIV envelope cytoplasmic tail. Retrovirology (2013) 0.90
Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design. Curr Top Med Chem (2011) 0.85
Caveolin-1 suppresses human immunodeficiency virus-1 replication by inhibiting acetylation of NF-κB. Virology (2012) 0.83
Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein. J Mol Biol (2016) 0.82
Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail. J Virol (2009) 0.80
Study of the HIV-2 Env cytoplasmic tail variability and its impact on Tat, Rev and Nef. PLoS One (2013) 0.76
HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. Microbiol Mol Biol Rev (2016) 0.75
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Lipid rafts and signal transduction. Nat Rev Mol Cell Biol (2000) 25.87
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retroviruses (1990) 5.79
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci U S A (2006) 4.15
Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci U S A (1993) 4.11
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol (1996) 4.08
The prevalence of antiretroviral drug resistance in the United States. AIDS (2004) 3.90
Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol (1994) 3.59
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol (2006) 3.59
Sequence-specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide. Proc Natl Acad Sci U S A (1981) 3.13
SIV adaptation to human cells. Nature (1989) 3.09
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A (1992) 3.01
Quantitative separation of murine leukemia virus proteins by reversed-phase high-pressure liquid chromatography reveals newly described gag and env cleavage products. J Virol (1984) 2.91
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol (1993) 2.80
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci U S A (2000) 2.70
Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology (2000) 2.60
Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses (2001) 2.60
The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J Virol (1989) 2.46
Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44
A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J Virol (1995) 2.35
Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J Clin Virol (2001) 2.27
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol (2002) 2.23
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain. J Virol (1994) 2.00
Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99
Role of lipid rafts in virus replication. Adv Virus Res (2005) 1.89
A viral protease-mediated cleavage of the transmembrane glycoprotein of Mason-Pfizer monkey virus can be suppressed by mutations within the matrix protein. Proc Natl Acad Sci U S A (1992) 1.83
Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol (2002) 1.81
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Synthesis and processing of the transmembrane envelope protein of equine infectious anemia virus. J Virol (1990) 1.75
Lipid rafts and pseudotyping. J Virol (2001) 1.75
Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS (2002) 1.55
Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide. J Virol (2003) 1.48
Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res Hum Retroviruses (2003) 1.43
Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions. J Virol (2000) 1.38
Prevalence of antibodies to SIV in baboons in their native habitat. AIDS Res Hum Retroviruses (1989) 1.23
A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J Biol Chem (1993) 1.13
Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. J Biol Chem (2006) 1.11
Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. J Virol (1998) 0.99
Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity. Virology (2005) 0.94
Multiple residues in the extracellular domains of CCR3 are critical for coreceptor activity. Virology (2004) 0.77
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A (2002) 4.14
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci U S A (2004) 3.90
Retrovirus budding. Virus Res (2004) 3.66
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol (2006) 3.59
Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol (2004) 3.22
Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A (2003) 3.02
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem (2004) 3.01
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol (2002) 2.66
Real-time visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog (2008) 2.32
Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1. Nat Rev Microbiol (2007) 2.08
Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem (2004) 2.07
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Human immunodeficiency virus type 1 assembly, release, and maturation. Adv Pharmacol (2007) 1.90
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. Blood (2012) 1.90
Role of lipid rafts in virus replication. Adv Virus Res (2005) 1.89
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol (2004) 1.89
Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. J Virol (2003) 1.79
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol (2006) 1.70
A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol (2008) 1.70
Ion-abrasion scanning electron microscopy reveals surface-connected tubular conduits in HIV-infected macrophages. PLoS Pathog (2009) 1.70
Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology (2006) 1.69
Structural basis for viral late-domain binding to Alix. Nat Struct Mol Biol (2007) 1.69
Equine infectious anemia virus and the ubiquitin-proteasome system. J Virol (2002) 1.63
Late domain-dependent inhibition of equine infectious anemia virus budding. J Virol (2004) 1.57
Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. J Virol (2005) 1.55
Lipids and membrane microdomains in HIV-1 replication. Virus Res (2009) 1.51
Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology (2006) 1.49
Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48
An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. J Biol Chem (2006) 1.44
Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses (2004) 1.42
Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 1.41
Point mutations in the HIV-1 matrix protein turn off the myristyl switch. J Mol Biol (2006) 1.38
A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry (2003) 1.37
Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. J Virol (2006) 1.35
Retroviruses have differing requirements for proteasome function in the budding process. J Virol (2003) 1.34
Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol (2009) 1.33
HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J Virol (2010) 1.33
Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles. J Virol (2003) 1.32
Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. J Mol Biol (2008) 1.31
Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag. Virology (2006) 1.30
Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs. PLoS Pathog (2008) 1.29
Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J Virol (2003) 1.24
Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology (2010) 1.24
A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41. J Virol (2006) 1.22
Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant. J Virol (2003) 1.21
Distribution of ESCRT machinery at HIV assembly sites reveals virus scaffolding of ESCRT subunits. Science (2014) 1.19
Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J Virol (2007) 1.18
Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol (2009) 1.18
New insights into HIV assembly and trafficking. Physiology (Bethesda) (2011) 1.18
Functional role of Alix in HIV-1 replication. Virology (2009) 1.16
Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol (2013) 1.16
Novel targets for HIV therapy. Antiviral Res (2008) 1.15
Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment. J Virol (2009) 1.15
Functional replacement of a retroviral late domain by ubiquitin fusion. Traffic (2008) 1.14
Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets (2009) 1.13
Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. J Biol Chem (2006) 1.11
HIV type 1 Gag as a target for antiviral therapy. AIDS Res Hum Retroviruses (2011) 1.08
GGA and Arf proteins modulate retrovirus assembly and release. Mol Cell (2008) 1.07
The Role of Lipids in Retrovirus Replication. Viruses (2010) 1.07
The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology (2010) 1.07
Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. J Biol Chem (2007) 1.06
Structural and functional insights into the HIV-1 maturation inhibitor binding pocket. PLoS Pathog (2012) 1.06
Molecular characterization of feline immunodeficiency virus budding. J Virol (2007) 1.04
Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction. Structure (2010) 1.04
Multifunctional RNA nanoparticles. Nano Lett (2014) 1.03
A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition. J Virol (2013) 1.02
A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat. Antimicrob Agents Chemother (2011) 1.01
Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol (2005) 1.01
The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability. Virology (2011) 0.99
Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain. Retrovirology (2011) 0.99
Structure-based in silico identification of ubiquitin-binding domains provides insights into the ALIX-V:ubiquitin complex and retrovirus budding. EMBO J (2013) 0.98
Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture. Protein Expr Purif (2005) 0.98
HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. Virology (2008) 0.96
Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. Biochemistry (2008) 0.95
Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J Virol (2006) 0.94
Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer. J Biol Chem (2013) 0.94
Myristate exposure in the human immunodeficiency virus type 1 matrix protein is modulated by pH. Biochemistry (2010) 0.94
Methods for the study of HIV-1 assembly. Methods Mol Biol (2009) 0.94